Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
US Army
Boehringer Ingelheim

Generated: March 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020951

« Back to Dashboard

NDA 020951 describes TAGAMET HB 200, which is a drug marketed by Glaxosmithkline and is included in one NDA. Additional details are available on the TAGAMET HB 200 profile page.

The generic ingredient in TAGAMET HB 200 is cimetidine. There are twenty-five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the cimetidine profile page.
Summary for 020951
Tradename:TAGAMET HB 200
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 020951

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SUSPENSION;ORALStrength200MG/20ML
Approval Date:Jul 9, 1999TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.